{"id":"W3088078660","doi":"10.1200/jco.20.00948","title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"National Cancer Institute; University of California, San Diego; University of Texas MD Anderson Cancer Center; National Institutes of Health; Apellis Pharmaceuticals; BeiGene; National Comprehensive Cancer Network; University of Nebraska Medical Center; Universiteit van Amsterdam; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine; AstraZeneca; Loxo Oncology; TG Therapeutics; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Regimen; Hazard ratio; Oncology; Progression-free survival; Gastroenterology; Alemtuzumab; Minimal residual disease; Leukemia; Chemotherapy; Lymphoma; Confidence interval; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007066775,0.0001488859,0.001646331,0.0001085346,0.00004245369,0.000008198866,0.0002119661,0.000246656,0.00007447821],"category_scores_gemma":[0.006806572,0.00009791143,0.0002426684,0.0002396445,0.0006946064,0.0000682865,0.0001368926,0.0007586842,0.000003468236],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.04597879,"about_ca_system_score_gemma":0.1263031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004062126,"about_ca_topic_score_gemma":0.0006035519,"domain_scores_codex":[0.9943178,0.001502245,0.002887968,0.0002843237,0.0007842846,0.0002234102],"domain_scores_gemma":[0.9925478,0.004629144,0.001631633,0.000286228,0.0005931233,0.0003120403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5136901,0.01014469,0.04675614,0.0006362555,0.01078045,0.00308753,0.04089447,0.1549159,0.04611804,0.0001102554,0.003675311,0.1691908],"study_design_scores_gemma":[0.4407714,0.0239905,0.191423,0.00009390489,0.0009238215,0.0001420437,0.0008300397,0.3413454,0.0001093452,0.0002651792,0.00003287625,0.00007251453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964168,0.001641179,0.00002272468,0.0006459331,0.000109509,0.001004825,0.00005182113,0.000003778489,0.0001034152],"genre_scores_gemma":[0.9985914,0.0004478488,0.0003806354,0.0001155122,0.0004244075,0.000006615598,0.00001452045,0.00001522358,0.000003852388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1864295,"threshold_uncertainty_score":0.9576835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2785272315645372,"score_gpt":0.5228803570445849,"score_spread":0.2443531254800477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}